Compare TRNR & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRNR | ARTL |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.5M |
| IPO Year | 2023 | 2014 |
| Metric | TRNR | ARTL |
|---|---|---|
| Price | $1.76 | $2.66 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 31.7K | ★ 1.2M |
| Earning Date | 11-16-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,530,000.00 | N/A |
| Revenue This Year | $117.64 | N/A |
| Revenue Next Year | $10.59 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 114.31 | N/A |
| 52 Week Low | $1.70 | $0.52 |
| 52 Week High | $3,378.70 | $179.19 |
| Indicator | TRNR | ARTL |
|---|---|---|
| Relative Strength Index (RSI) | 24.04 | 34.20 |
| Support Level | N/A | $0.52 |
| Resistance Level | $3.23 | $6.81 |
| Average True Range (ATR) | 0.12 | 0.19 |
| MACD | 0.23 | -0.01 |
| Stochastic Oscillator | 14.08 | 0.00 |
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.